Literature DB >> 18976132

Acyclovir delivery systems.

Rita Cortesi1, Elisabetta Esposito.   

Abstract

Herpes viruses (herpes simplex, varicella zoster, cytomegalovirus) are the main cause of a wide variety of human infections. Although the development of successful antiviral agents against infections caused by herpes viruses had been slow until the last decade, the production of delivery systems for acyclovir are a promising alternative. The present review summarizes the principal advances made in developing carriers for the delivery of acyclovir by different routes of administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976132     DOI: 10.1517/17425240802450340

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  6 in total

1.  Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection.

Authors:  Gajanand Sharma; Kanika Thakur; Arvind Setia; Basant Amarji; Mini P Singh; Kaisar Raza; Om Prakash Katare
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

2.  Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.

Authors:  Jwala Jwala; Sai H S Boddu; Sujay Shah; Suman Sirimulla; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-04       Impact factor: 2.671

3.  Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity.

Authors:  Abdullah M Al-Alawi; Juhaina Salim Al-Maqbali; Maria Al-Adawi; Anan Al-Jabri; Henrik Falhammar
Journal:  Saudi Pharm J       Date:  2022-03-26       Impact factor: 4.562

4.  Feasibility of Enhancing Skin Permeability of Acyclovir through Sterile Topical Lyophilized Wafer on Self-Dissolving Microneedle-Treated Skin.

Authors:  Uzair Nagra; Kashif Barkat; Muhammad U Ashraf; Maryam Shabbir
Journal:  Dose Response       Date:  2022-05-16       Impact factor: 2.623

5.  Pluronic F127-tailored lecithin organogel of acyclovir: preclinical evidence of antiviral activity using BALB/c murine model of cutaneous HSV-1 infection.

Authors:  Gajanand Sharma; Bimaldeep Kaur; Kanika Thakur; Akanksha Mahajan; Basant Amarji; Mini P Singh; Om Prakash Katare
Journal:  Drug Deliv Transl Res       Date:  2021-01-23       Impact factor: 4.617

6.  Volatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections.

Authors:  James R Stegman; Jill K Badin; Kaitlyn A Biles; Thamar Etienne; Sogand Fartash-Naini; Ariel D Gordon; Zachary W Greeley; Benjamin W Harding; Ricardo J Mack; Danielle Masica; Ashley N Nelson; Amandeep K Samra; Sarah E Smith; Gabrielle P Thomas; Haley J Zack; Timothy J Brunker; Barry J Margulies
Journal:  J Drug Deliv       Date:  2018-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.